leadf
logo-loader
viewIntegumen

Integumen clinches partnerships to tackle coronavirus pandemic

Snapshot

 

  • Lead product is Labskin, a laboratory-grown skin that avoids animal testing.
  • Company has moved into real-time testing of water quality
  • Name to change to DeepVerge PLC

 

woman touching her skin

Quick facts: Integumen

Price: 33.5 GBX

AIM:SKIN
Market: AIM
Market Cap: £37.92 m
Follow

What it does

Integumen PLC's (LON:SKIN) backbone of the company is a product called Labskin, a laboratory-grown skin that is used by cosmetics and pharmaceutical companies to see how their latest products will react with human skin.

Labskin gives scientists a much better idea of how their cream or gel or make-up will react in the real world.

Not only does it make animal testing redundant, the added accuracy it gives researchers reduces R&D costs by helping to improve success rates.

Other activities

It owns STOER, a premium skincare range for men and also has a 9.35% stake in Cellulac, which produces biodegradable plastic ingredients and natural oils.

Growth drivers

With the help of artificial intelligence firm Rinocloud, which it bought in April, Integumen is building Labskin-on-a-chip, which will record every treatment tested on the platform and store its effects in a database.

That will give every dermatology clinic with a computer the ability to take a swab of a patient’s own skin bacteria, place it on the Labskin platform, run it against the database, and advise what the best course of treatment might be.

Then there’s Labskin AI, a digital extension to the lab-grown skin to clone the skin of volunteers in clinical trials.

The company said the new test would cut the number of volunteers required for trials by 50%, reducing recruitment times and project management costs.

 

How it is doing 

Revenue for the current year is expected to be £4mln said Integumen, which will soon be renamed DeepVerge PLC.

Achieving that target will see a significant ramp-up. The company generated some £1mln of revenue in the first six months of 2020, and it expected to bring in another £1mln in the third quarter and then the fourth.

The company reported a £611,000 gross profit for the first half, it made a £552,000 underlying loss (EBITDA before exceptional items), and net profit was marked at £925,000.

Chief executive Gerard Brandon pointed out that the business continues to grow and evolve via collaboration and acquisition.

Most recently, in August, the company agreed to a £21.25mln merger with Modern Water PLC (LON:MWG).

In September, it signed an MoU with the WaterRising Institute to supply equipment to detect pathogens including COVID-19 in the Great Lakes region in Michigan.

The WaterRising Institute is a not-for-profit organisation that aims to provide real-time alerts to identify sources of water pollution.

What the boss says: chief executive Gerry Brandon

“COVID-19 contamination detection in wastewater increasingly becomes an important tool in the fight against the disease,"

Video 

 

What the broker says: Turner Pope

“Given the anticipated need for such safety equipment, this first-mover advantage derived from combination of proprietary technologies could potentially create a transformative future opportunity."

“Notwithstanding this, the addition of value and opportunity through the Group’s [Integumen’s] AI division is already opening other options to develop data analytic tools/facilities for Modern Water monitoring equipment, with the potential to include ‘bolt-on’ services in anticipation of new longer-term national requirements and scope to secure higher client revenues."

“This, together with ongoing expansion of Rinocloud’s high margin data and AI services, Labskin’s analytical/monitoring technologies and the extended customer reach being offered through ecowaterOS’s multi-continental consortium, highlights the scale of opportunities being presented to Integumen in its underserved global markets.”

Inflexion points

  • Sales start to accrue from Modern Water merger
  • Partnerships with Avacta, Aptamer continue to develop
  • Labskin sales gain momentum
  • Revenue grows four-fold

 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Integumen PLC to seek fast-track approval for its new coronavirus breath test

Integumen PLC's (LON:SKIN) Gerry Brandon speaks to Proactive's Andrew Scott after unveiling a new personalised coronavirus breath test, Microtox BT, and a complimentary digital health pass platform which he says has the potential to enable instant real-time testing for the virus. Brandon says...

1 week, 1 day ago

3 min read